Collectively, novel therapeutic windows and compounds offer promise for effectively combating intussusceptive angiogenesis and VEGF-overexpressed-ARDS following SARS-CoV-2 infection (Figure 1). This evidence concerns the gene VEGFA and acute respiratory distress syndrome.